Dupilumab has demonstrated efficacy with acceptable safety in clinical trials in patients with moderate-to-severe atopic dermatitis (AD).
To assess dupilumab’s impact on asthma and sinonasal conditions in adult patients with moderate-to-severe AD in 4 randomized, double-blinded, placebo-controlled trials.
In LIBERTY AD SOLO 1 (NCT02277743), SOLO 2 (NCT02755649), CHRONOS (NCT02260986), and CAFÉ (NCT02755649), patients received placebo, dupilumab 300 mg every 2 weeks (q2w), or dupilumab 300 mg weekly (qw). In CHRONOS and CAFÉ, patients received concomitant topical corticosteroids. This post hoc analysis assessed Asthma Control Questionnaire-5 (ACQ-5) scores in patients with asthma, Sino-Nasal Outcome Test-22 (SNOT-22) scores in patients with sinonasal conditions, and AD signs and symptoms in all patients.
Of the 2,444 patients, 463 (19%) had asthma with baseline ACQ-5 ≥ 0.5; 1,171 (48%) had sinonasal conditions; and 311 (13%) had both. At Week 16, ACQ-5 scores improved by (least squares mean change from baseline [standard error]) 0.27 (0.07), 0.59 (0.08), and 0.56 (0.07) in placebo-, q2w-, and qw-treated patients with asthma, respectively, while SNOT-22 scores improved by 5.1 (0.8), 9.9 (0.9), and 10.8 (0.8) in patients with sinonasal conditions (P<.01 for all dupilumab vs placebo). Improvements in ACQ-5 and SNOT-22 were also seen in patients with both conditions. Dupilumab also significantly improved AD signs and symptoms among all subgroups.
In this first analysis of patients with comorbid moderate-to-severe AD, asthma, and/or chronic sinonasal conditions, dupilumab improved all 3 diseases in a clinically meaningful and statistically significant (vs placebo) manner, based on validated outcome measures.

Copyright © 2021. Published by Elsevier Inc.